Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
Elnaggar M, Agte S, Restrepo P, Ram M, Melnekoff D, Adamopoulos C, Stevens MM, Kappes K, Leshchenko V, Verina D, Jagannath S, Poulikakos PI, Parekh S, Laganà A. Elnaggar M, et al. Among authors: agte s. J Hematol Oncol. 2022 Aug 17;15(1):109. doi: 10.1186/s13045-022-01330-3. J Hematol Oncol. 2022. PMID: 35978321 Free PMC article.
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma.
Van Oekelen O, Gleason CR, Agte S, Srivastava K, Beach KF, Aleman A, Kappes K; PVI/Seronet team; Mouhieddine TH, Wang B, Chari A, Cordon-Cardo C, Krammer F, Jagannath S, Simon V, Wajnberg A, Parekh S. Van Oekelen O, et al. Among authors: agte s. Cancer Cell. 2021 Aug 9;39(8):1028-1030. doi: 10.1016/j.ccell.2021.06.014. Epub 2021 Jun 29. Cancer Cell. 2021. PMID: 34242572 Free PMC article. No abstract available.
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma.
Aleman A, Upadhyaya B, Tuballes K, Kappes K, Gleason CR, Beach K, Agte S, Srivastava K; PVI/Seronet Study Group; Van Oekelen O, Barcessat V, Bhardwaj N, Kim-Schulze S, Gnjatic S, Brown B, Cordon-Cardo C, Krammer F, Merad M, Jagannath S, Wajnberg A, Simon V, Parekh S. Aleman A, et al. Among authors: agte s. Cancer Cell. 2021 Nov 8;39(11):1442-1444. doi: 10.1016/j.ccell.2021.09.015. Epub 2021 Oct 19. Cancer Cell. 2021. PMID: 34706273 Free PMC article. No abstract available.
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients.
Aleman A, Van Oekelen O, Upadhyaya B, Beach K, Kogan Zajdman A, Alshammary H, Serebryakova K, Agte S, Kappes K, Gleason CR, Srivastava K; PVI/MM/Seronet Study Group; Almo S, Cordon-Cardo C, Krammer F, Merad M, Jagannath S, Wajnberg A, Simon V, Parekh S. Aleman A, et al. Among authors: agte s. Cancer Cell. 2022 May 9;40(5):441-443. doi: 10.1016/j.ccell.2022.03.013. Epub 2022 Apr 6. Cancer Cell. 2022. PMID: 35390296 Free PMC article. No abstract available.
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma.
Restrepo P, Bhalla S, Ghodke-Puranik Y, Aleman A, Leshchenko V, Melnekoff DT, Agte S, Jiang J, Madduri D, Richter J, Richard S, Chari A, Cho HJ, Jagannath S, Walker CJ, Landesman Y, Laganà A, Parekh S. Restrepo P, et al. Among authors: agte s. JCO Precis Oncol. 2022 Jun;6:e2200147. doi: 10.1200/PO.22.00147. JCO Precis Oncol. 2022. PMID: 35704796 Free PMC article.
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.
Mouhieddine TH, Van Oekelen O, Melnekoff DT, Li J, Ghodke-Puranik Y, Lancman G, Thibaud S, Pan D, Rajeeve S, Agte S, Aleman A, Sanchez L, Richard S, Rossi A, Richter J, Cho HJ, Rodriguez C, Lagana A, Moshier E, Chari A, Jagannath S, Parekh S. Mouhieddine TH, et al. Among authors: agte s. Blood Adv. 2023 Mar 28;7(6):1056-1064. doi: 10.1182/bloodadvances.2022007923. Blood Adv. 2023. PMID: 36018226 Free PMC article. Clinical Trial.
A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements.
Kimmerling RJ, Stevens MM, Olcum S, Minnah A, Vacha M, LaBella R, Ferri M, Wasserman SC, Fujii J, Shaheen Z, Sundaresan S, Ribadeneyra D, Jayabalan DS, Agte S, Aleman A, Criscitiello JA, Niesvizky R, Luskin MR, Parekh S, Rosenbaum CA, Tamrazi A, Reid CA. Kimmerling RJ, et al. Among authors: agte s. Commun Biol. 2022 Nov 26;5(1):1295. doi: 10.1038/s42003-022-04270-3. Commun Biol. 2022. PMID: 36435843 Free PMC article.
Publisher Correction: A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements.
Kimmerling RJ, Stevens MM, Olcum S, Minnah A, Vacha M, LaBella R, Ferri M, Wasserman SC, Fujii J, Shaheen Z, Sundaresan S, Ribadeneyra D, Jayabalan DS, Agte S, Aleman A, Criscitiello JA, Niesvizky R, Luskin MR, Parekh S, Rosenbaum CA, Tamrazi A, Reid CA. Kimmerling RJ, et al. Among authors: agte s. Commun Biol. 2023 Jan 6;6(1):15. doi: 10.1038/s42003-022-04376-8. Commun Biol. 2023. PMID: 36609595 Free PMC article. No abstract available.
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
Elnaggar M, Agte S, Restrepo P, Ram M, Melnekoff D, Adamopoulos C, Stevens MM, Kappes K, Leshchenko V, Verina D, Jagannath S, Poulikakos PI, Parekh S, Laganà A. Elnaggar M, et al. Among authors: agte s. J Hematol Oncol. 2023 May 8;16(1):52. doi: 10.1186/s13045-023-01449-x. J Hematol Oncol. 2023. PMID: 37158935 Free PMC article. No abstract available.
24 results